A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase 3 Study of Orelabrutinib in Combination with Rituximab and Bendamustine (BR) vs. BR in Subjects with Treatment-Naїve Mantle Cell Lymphoma
This study is for people recently diagnosed with a specific type of blood cancer called Mantle Cell Lymphoma (MCL). It’s a Phase 3 study, meaning it’s a big, important trial to confirm if a new treatment works. Doctors want to see if adding a new drug, orelabrutinib, to the usual treatment (rituximab and bendamustine) helps people live longer without their cancer getting worse. They'll compare this combination to the usual treatment alone. The study will also look at how long people live overall, how well the cancer responds, and whether the new treatment causes any side effects. It's a 'double-blind' study, so neither patients nor their doctors will know who is getting the new drug and who is getting a dummy pill.
At a glance
What is this study about?
Imagine you have a type of blood cancer called Mantle Cell Lymphoma (MCL) and you haven't been treated for it yet. This study is designed specifically for people in your situation. Doctors are always looking for better ways to treat cancer, and this study focuses on seeing if a newer medication can improve on the standard treatment.
The usual treatment for MCL often involves a combination of drugs called rituximab and bendamustine. This study wants to find out if adding another drug, orelabrutinib, to this standard combination makes the treatment more effective. They'll compare the group receiving the new drug plus standard treatment to another group receiving only the standard treatment. The main goal is to see if adding orelabrutinib helps people live longer without their cancer getting worse, which is a very important measure in cancer care.
Because it’s a 'Phase 3' study, it means it's one of the final steps before a new treatment might become widely available. The study is also 'double-blind', which means neither you nor your doctors will know whether you are receiving the new drug or a dummy pill (placebo) alongside the standard treatment. This helps make the study results as fair and accurate as possible, so we can clearly see if the new drug has a real effect. Everything will be carefully checked by an independent group of experts.
Key takeaways
- This study is testing a new drug for people with newly diagnosed Mantle Cell Lymphoma.
- It compares a new treatment combination against the standard treatment.
- The main goal is to see if the new treatment helps people live longer without their cancer worsening.
- It's a large, important study ('Phase 3') to confirm if the new drug works.
- Both patients and doctors won't know which treatment group you are in.
- Participation is voluntary, and you can withdraw at any time.
Who may be eligible?
This study is for adults, aged 18 or older. It is open to both men and women.
To be considered for this study, you must have been recently diagnosed with Mantle Cell Lymphoma and not have received any previous treatment for it. The doctors will also check other health conditions to make sure it's safe for you to take part.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you recently been diagnosed with Mantle Cell Lymphoma?
- Have you NOT received any previous treatment for your Mantle Cell Lymphoma?
- Are you generally healthy enough to participate in a clinical trial (your doctor will check this)?
- Are you willing to have regular hospital visits and check-ups?
What does participation involve?
If you decide to take part in this study, you would be randomly assigned to one of two treatment groups. One group will receive the standard treatment (rituximab and bendamustine) plus the new study drug (orelabrutinib), while the other group will receive the standard treatment plus a dummy pill that looks exactly like orelabrutinib.
You would have regular visits to the hospital for your treatments and to have check-ups. These check-ups will include blood tests, physical examinations, and scans to monitor your health and how your cancer is responding. Doctors will also ask you questions about your quality of life and how you’re feeling. The exact number of visits and the full duration of the study will be explained in detail by the study team, but generally, this type of study involves treatments over several months, followed by ongoing monitoring.
Potential risks and benefits
Locations (2)
- —UnverifiedFrance
- —UnverifiedCzechia
Common questions
What is Mantle Cell Lymphoma?
It's a rare type of blood cancer that affects certain white blood cells called B-lymphocytes. It can be challenging to treat.
What does 'double-blind' mean?
It means neither you nor your doctors will know if you are getting the new drug or a dummy pill. This helps ensure fair and accurate results.
What is a 'Phase 3' study?
It's a large study, usually one of the last steps, to confirm if a new treatment is safe and effective compared to existing treatments.
Will I still get standard treatment?
Yes, both groups in the study will receive the standard treatment for Mantle Cell Lymphoma (rituximab and bendamustine).
What if I don't want to continue in the study?
You can leave the study at any time, for any reason, and it won't affect your future medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.